Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
All content for Oncology Decoded is the property of Oncology Decoded and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
18: What Were The Most Impactful GU Oncology Data From ESMO 2025?
Oncology Decoded
46 minutes
2 months ago
18: What Were The Most Impactful GU Oncology Data From ESMO 2025?
Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.
Oncology Decoded
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
